ASPIC

Um estudo internacional envolvendo 56 investigadores e clínicos de nove países, liderado pela cientista Carla Oliveira, do Instituto de Investigação e Inovação em Saúde da Universidade do Porto (i3S), e publicado na prestigiada revista GUT, definiu novas causas de risco genético de cancro gástrico e mamário e critérios clínicos para os identificar.

A groundbreaking international study has provided critical insights into the role of CTNNA1 gene variants in hereditary diffuse gastric cancer (HDGC), revealing new associations with cancer risk and paving the way for improved genetic testing and clinical management of affected individuals.

The study involved 56 researchers and clinicians from 9 countries, from the European and American continents, led by an i3S team in Porto.

Tubo-ovarian carcinoma remains a leading cause of gynaecological-related mortality and continues to lack robust preclinical models that accurately reflect its biological heterogeneity. Through a joint effort between Gulbenkian Institute of Molecular Medicine and CUF Descobertas Hospital, the research team established patient-derived organoids from high- and low-grade serous carcinoma, as well as normal fallopian tube. Despite the limited cohort, the organoids preserved the morphological and immunophenotypical features of the original tissues.

O carcinoma tubo-ovárico constitui uma das principais causas de mortalidade ginecológica e carece de modelos pré-clínicos que reproduzam de forma fidedigna a sua heterogeneidade biológica. Neste estudo, resultado da colaboração entre o Gulbenkian Institute of Molecular Medicine e o Hospital CUF Descobertas, foram estabelecidos organóides derivados de doentes, a partir de carcinomas serosos de alto e baixo grau, e de trompa de Falópio normal, preservando as características morfológicas e imunofenotípicas dos tecidos de origem.

Researchers from the Epigenetics & Cancer Biology Group at the IPO Porto Research Center, in collaboration with the Pathology and Clinical Pathology Services, have developed an algorithm to improve the screening of women who test positive for HPV infection in the Population Cervical Cancer Screening Program implemented in the Northern region of the country. Based on DNA methylation markers and combined with HPV genotyping information, this algorithm reduces the number of women referred for a Cervical Pathology consultation and possible colposcopy.

Investigadores do Grupo de Epigenética & Biologia do Cancro, do Centro de Investigação do IPO Porto em colaboração com os Serviços de Anatomia Patológica e de Patologia Clínica, desenvolveram um algoritmo para melhorar a triagem das mulheres que testam positivo para infeção por HPV no Programa de Rastreio Populacional do Cancro do Colo do Útero, implementado na região Norte do País.

A team from the Institute for Research and Innovation in Health at the University of Porto (i3S), led by Salomé Pinho, has discovered a new strategy to make (CAR-)T cell therapies more effective against solid tumors. The findings were published in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR).

Uma equipa do Instituto de Investigação e Inovação em Saúde da Universidade do Porto (i3S), liderada por Salomé Pinho, descobriu uma nova estratégia de tornar as terapias com células T (CAR-T) mais eficazes contra tumores sólidos. Os resultados foram publicados na revista Cancer Immunology Research, da American Association for Cancer Research(AACR).

Soft tissue sarcomas (STS) are a rare and heterogeneous group of malignant tumors, which makes their diagnosis and treatment particularly challenging. Available treatments remain largely ineffective for many patients, leading to disease progression and low survival rates.

Os sarcomas de tecidos moles (STS) são um grupo raro e heterogéneo de tumores malignos, o que torna o seu diagnóstico e tratamento particularmente desafiantes. Os tratamentos disponíveis continuam a ser pouco eficazes para muitos doentes, levando à progressão da doença e a uma baixa taxa de sobrevivência.